Just days after completing the world’s first ketamine treatment study for behavioral addictions, Awakn Life Sciences Corp. (NEO: AWKN)(OTCMKTS: AWKNF) has moved to protect its intellectual property. The company announced the filing of a Patent Cooperation Treaty (PCT) application for the treatment of behavioral addictions with ketamine and ketamine-assisted psychotherapy based on data provided from the study, announced May 19. TDR interviewed CEO Anthony Tennyson to glean the significance of it all.
To recap, last Friday’s pilot ketamine treatment study for behavioral addictions was an important development. The study investigated ketamine as a new treatment approach for behavioral addictions by re-wiring pathways in the brain that can change behavior. The results demonstrated potentially novel mechanisms that merit a larger study and further exploration, which the company is now exploring. As indicated, the study formed the based on the PCT just filed by Awakn Life Sciences and announced today.
Speaking on the granularity of the patent application, Mr. Tennyson reminds us that some behavioral addiction treatments barely have defined treatment programs as it is, let alone ones that are effective. Behavioral disorders run the gamut from the relatively common, such as gambling and compulsive sexual behavior, to the arcane delinquencies such as internet and shopping addictions.
The standard of care for behavioral disorders is even worse—it’s barely existent. And so what we did is we initiated and we just completed the first studies of their kind in the world to develop—to begin to develop the pathway to develop pharmacological or drug-based treatments for these chronic behavioral addictions. We completed that study a couple of weeks ago, we announced the results a couple of weeks ago, and now just today, we’ve announced the filing of patents—or very recently the filing of patents—based upon the data developed in that early stage study.
The significance of today’s Patent Cooperation Treaty (PCT) application cannot be understated. If successful, it would protect the company IP for all behavior addictions treated with ketamine in the United States. By extension, it could grant Awakn exclusivity in the commercial development of ketamine, its metabolites and derivatives to treat a wide swath of behavioral addictions.
Click on the embedded link to view our latest interview with Awakn Life Sciences CEO, Anthony Tennyson.
* In accordance with an executed agreement between The Dales Report and Awakn Life Sciences, The Dales Report is engaged with the aforementioned on a current 4-month contract and has received 125,000 common shares for services rendered included in the agreement, with the purpose of publicly disseminating information pertaining to Awakn Life Sciences via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer .